MedTrace Logo

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

NCT07521241 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-04-13

No results posted yet for this study

Summary

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Conditions

  • Chronic Liver Disease (CLD)

Interventions

DRUG

AD-230, AD-2301

Oral administration of AD-230 or AD-2301, according to randomized sequence.

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2026-06-30
Completion
2026-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07521241 on ClinicalTrials.gov